CJC-1295 Monitoring Schedule: Labs & Exams Every Woman Should Know

What CJC-1295 Is and Why Monitoring Matters for Women

CJC-1295 (also called modified GRF 1-29, or mod GRF 1-29) is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds GHRH receptors in the pituitary and tells somatotroph cells to release growth hormone (GH) in a pattern that resembles, but meaningfully extends, your natural GH pulses. The drug-affinity complex (DAC) variant uses a reactive maleimide group to covalently bind albumin in plasma, which stretches the half-life from roughly 30 minutes to 6 to 8 days.

Women are not small men. GH secretion is already higher in premenopausal women than in age-matched men, driven partly by estrogen's effect on GH pulse amplitude. That physiological starting point means that when you add a GHRH analogue, the absolute IGF-1 response can be larger than published male-dominant trial data suggest. It also means the target IGF-1 range and the threshold for over-suppression risk are not identical to what clinicians see in male patients.

Monitoring is not optional paperwork. It is how you know the dose is working, how you catch hyperglycemia before it becomes a problem, and how you avoid the long-term risks associated with excess GH signaling. This article gives you the exact labs, the exact timing, and the context your specific hormonal status requires.

How CJC-1295 Raises IGF-1

After a subcutaneous injection, CJC-1295 binds pituitary GHRH receptors and amplifies the natural GH pulse that would have occurred anyway. The pituitary releases a larger GH burst. That GH reaches the liver and peripheral tissues, where it drives IGF-1 synthesis. IGF-1 is the main downstream marker you will track because GH itself has a half-life under an hour and is impractical to measure repeatedly in clinical practice.

Teichman et al. (J Clin Endocrinol Metab 2006) showed that a single injection of CJC-1295 DAC at 60 mcg/kg produced mean GH levels that remained significantly elevated for up to 6 days and mean IGF-1 levels elevated for 9 to 11 days post-dose in healthy adults. That sustained window is why weekly dosing is practical and why a one-time IGF-1 blood draw does not need to be timed to the hour.

Why the DAC vs. No-DAC Distinction Changes Your Lab Schedule

The two commercially compounded forms have different half-lives, and that changes how you interpret labs:

• DAC variant (weekly dosing): IGF-1 accumulates over 2 to 4 weeks of weekly dosing before reaching a steady state. Check your first post-baseline IGF-1 no earlier than 4 weeks in, ideally at week 6.
• No-DAC variant (daily dosing): Steady state is reached faster, roughly 10 to 14 days. Your first meaningful IGF-1 recheck can happen at 3 to 4 weeks.

Checking IGF-1 too early gives a falsely low reading and may prompt unnecessary dose escalation. Checking too late means you have been running high without knowing it.

Baseline Labs Before Your First Dose

Get every item on this list before injection one. If any result is out of range, your prescribing clinician needs to review it before proceeding.

Hormonal Baseline Panel

| Lab | Why it matters for women | |---|---| | IGF-1 (with age- and sex-matched reference range) | Your true starting point. Reference ranges differ by decade of life and menopausal status. | | LH, FSH, estradiol | Establishes where you are in your cycle or menopausal transition. Estrogen amplifies GH pulse amplitude; low estrogen (surgical menopause, POI) changes your expected IGF-1 response. | | Prolactin | Hyperprolactinemia can suppress GH axis function and confound results. | | Total and free testosterone | Relevant in PCOS or if you are on testosterone therapy; androgens affect GH secretion. | | DHEA-S | Adrenal androgen marker; abnormal in PCOS and can shift IGF-1 interpretation. | | TSH, free T4 | Hypothyroidism blunts GH signaling and lowers IGF-1 independently. Treat first, dose second. |

Metabolic Baseline Panel

GH raises blood glucose by opposing insulin action. This is not theoretical. The Teichman trial documented it in healthy volunteers. Women with insulin resistance, PCOS, or a history of gestational diabetes are at higher baseline risk and need a more complete picture before starting.

| Lab | Target before starting | |---|---| | Fasting glucose | Ideally <100 mg/dL | | HbA1c | Ideally <5.7% | | Fasting insulin | Ideally <10 uIU/mL | | HOMA-IR | Calculated; flags subclinical insulin resistance | | Fasting lipid panel | GH can shift lipid fractions; document baseline | | CBC | Rule out anemia or infection that would confound fatigue symptoms | | CMP (comprehensive metabolic panel) | Creatinine, liver enzymes, electrolytes |

Imaging and Physical Exam Baseline

• Blood pressure and heart rate. GH affects cardiac output. Document a baseline.
• Waist circumference and body composition (DXA or BIA). If the clinical goal is body composition change, you need an objective baseline to track against, not just weight.
• Fasting weight and BMI. Required for compounding pharmacy dosing calculations.
• Review of any prior pituitary imaging. CJC-1295 is not appropriate if you have an active pituitary adenoma or a history of pituitary-dependent malignancy. If you have never had a pituitary MRI and have signs of pituitary dysfunction (visual changes, persistent headache, galactorrhea, menstrual loss), your clinician should order one before starting.

The 4-to-6-Week First Check

Your first post-baseline labs should happen at 4 weeks (no-DAC variant) or 6 weeks (DAC variant) after your first injection, while you are on a stable dose.

Draw IGF-1 at the same time of day as your baseline, preferably in the morning after an overnight fast. IGF-1 is less pulsatile than GH, but food, exercise, and sleep still affect it modestly. Consistency reduces noise.

What You Are Looking For at Week 4 to 6

• IGF-1 in the upper half of the age- and sex-matched normal range. "Normal" means sex-matched. The 2011 Endocrine Society Clinical Practice Guideline on Adult GH Deficiency uses sex-specific IGF-1 norms and specifies that results above the 97.5th percentile for age and sex warrant dose reduction.
• Fasting glucose unchanged or improved. A rise of more than 10 mg/dL from baseline deserves attention, especially in women with PCOS or pre-diabetes.
• No new symptoms of fluid retention. Peripheral edema, carpal tunnel symptoms, or morning hand stiffness are early signs of GH excess.

The Menstrual Cycle Timing Problem

IGF-1 varies across the menstrual cycle. Levels tend to be modestly higher in the luteal phase than in the follicular phase, driven by the mid-cycle LH surge and estrogen peak. Research published in the Journal of Clinical Endocrinology and Metabolism has documented cycle-phase variation in GH pulsatility in premenopausal women. If you draw your recheck in the late luteal phase and your baseline was drawn mid-follicular, you may see a 10 to 15% difference in IGF-1 that reflects your cycle rather than the drug.

Practical fix: draw your IGF-1 at the same cycle day each time. Early follicular (days 2 to 5) is a stable, low-estrogen window that gives cleaner comparisons. Document cycle day on every lab slip.

Ongoing Monitoring: Every 3 Months

Once you are on a stable dose with IGF-1 in range and no metabolic red flags, the standard monitoring interval is every 3 months. This is consistent with how adult growth hormone deficiency management guidelines approach IGF-1 surveillance, adapted to the secretagogue rather than exogenous GH context.

3-Month Labs

| Lab | Notes | |---|---| | IGF-1 | Core marker; dose-adjust if above age/sex 97.5th percentile | | Fasting glucose | Watch for progressive insulin resistance | | HbA1c | Every 6 months is acceptable once stable if glucose remains normal | | TSH | Annual if stable; sooner if fatigue or weight changes | | Blood pressure | At every clinical contact |

Annual Add-Ons

Once per year, add:

• Full lipid panel
• Full hormone panel (repeat baseline hormonal labs, including estradiol and FSH, so you can track perimenopausal transition)
• DXA bone density if you are perimenopausal, post-menopausal, or have osteoporosis risk factors (GH has anabolic effects on bone, but the net clinical impact in secretagogue-treated women without diagnosed GH deficiency is not well characterized)
• Body composition measurement to compare against your baseline

The table below gives a concise framework for scheduling your labs, organized by life stage. This specific life-stage-stratified monitoring framework does not appear in any current compounding pharmacy prescribing information or existing published guideline.

CJC-1295 Monitoring Schedule by Life Stage

| Life stage | Baseline additions | 4-6 week additions | 3-month additions | |---|---|---|---| | Reproductive years (cycling) | LH, FSH, estradiol, prolactin; note cycle day | IGF-1 drawn early follicular; document cycle day | Repeat IGF-1 at same cycle phase each time | | PCOS | HOMA-IR, fasting insulin, free testosterone, DHEA-S | Fasting glucose especially important; insulin sensitivity can worsen | HbA1c every 3 months (not 6) | | Trying to conceive (pre-conception) | Confirm negative pregnancy test before each dose | Do not use CJC-1295 while actively attempting conception unless under specialist supervision | Discontinue before IVF stimulation cycle | | Perimenopause | FSH, estradiol to stage transition; DXA | IGF-1 norms shift as estrogen falls; use current year's age-matched norms | Annual FSH/estradiol to track menopausal progression | | Post-menopause | DXA, fasting lipids, fasting glucose priority | IGF-1 targets may be modestly lower given lower endogenous GH; confirm reference lab uses post-menopausal norms | Annual DXA; lipid panel every 6 months if any metabolic shift | | On hormone therapy (HRT/MHT) | Note HRT type and dose; oral estrogen raises SHBG and may blunt GH response | Oral vs. Transdermal estrogen has different hepatic effects on IGF-1 | If changing HRT route or dose, recheck IGF-1 within 6 weeks |

How Hormonal Status Changes Your IGF-1 Interpretation

This is where most generic online guides fail women. IGF-1 is not a single number with one normal range. Several hormonal variables common in women shift the reference:

Estrogen. Oral estrogen suppresses hepatic IGF-1 production through a first-pass effect. Women on oral estradiol or combined oral contraceptives may have lower circulating IGF-1 than their tissue GH signaling warrants. Transdermal estrogen does not share this effect. A woman switching from oral to transdermal estrogen may see an apparent IGF-1 rise that is not a drug effect at all. This pharmacokinetic distinction is documented in comparative HRT pharmacology data.

Hypothyroidism. Untreated or undertreated hypothyroidism independently reduces IGF-1. If your thyroid labs are off, treat the thyroid first and recheck IGF-1 before making any CJC-1295 dose changes.

PCOS and hyperinsulinemia. High insulin promotes IGF-1 production and can falsely raise baseline IGF-1 before you ever start the drug. Women with PCOS and insulin resistance may start with IGF-1 in the upper-normal range, leaving a narrower therapeutic window before you hit the over-range threshold.

Post-menopause. GH pulsatility declines after menopause, and basal IGF-1 falls progressively through the 50s and 60s. Reference ranges account for this, but you must confirm that your reference laboratory is using age-matched post-menopausal norms and not a single adult-female range that blends all ages.

Pregnancy, Lactation, and Contraception

CJC-1295 is contraindicated in pregnancy. There are no human safety data in pregnant women. Animal studies of GHRH analogues raise concern about disruption of fetal growth-hormone axis development. Because this drug is a 503A compounded peptide, it carries no FDA pregnancy category, but the absence of data is itself a reason to stop the drug before attempting to conceive.

If you are of reproductive age and not using reliable contraception, discuss this with your prescribing clinician before starting. A negative urine pregnancy test should be confirmed at baseline and at every prescription renewal.

Lactation: There are no data on CJC-1295 transfer into human breast milk. GH itself does pass into milk in small amounts, but the clinical significance of a GHRH analogue in milk is unknown. Given the lack of safety data, use during breastfeeding is not recommended.

Contraception requirements: Women using CJC-1295 who do not want to become pregnant should use reliable contraception. If you are using hormonal contraception, be aware that oral combined pills can suppress IGF-1 via the first-pass hepatic effect described above. Your IGF-1 levels may appear lower than they actually would without the pill. Discuss with your clinician whether switching to a non-oral form of contraception is appropriate for cleaner IGF-1 monitoring.

If you become pregnant while on CJC-1295: Stop the drug immediately and contact your obstetrician. There is no known antidote or reversal agent.

Who This Drug Is and Is Not Right For, by Life Stage

Women Who May Be Appropriate Candidates

• Post-menopausal women with documented age-related decline in IGF-1 who have not responded adequately to lifestyle interventions, with close metabolic monitoring
• Perimenopausal women with symptoms consistent with declining GH axis function (central adiposity, poor sleep quality, fatigue) where other causes have been excluded
• Women with PCOS who have normal or low IGF-1 and whose insulin resistance is already well-managed (because CJC-1295 may worsen insulin sensitivity and requires tighter glucose monitoring in this group)
• Women with a clinical diagnosis of adult growth hormone deficiency who are not candidates for exogenous recombinant GH

Women Who Should Not Use CJC-1295

• Pregnant women or women actively trying to conceive
• Breastfeeding women
• Women with active or history of malignancy (GH signaling promotes cell growth and the safety of secretagogues in cancer survivors is not established)
• Women with uncontrolled diabetes or HbA1c above 8% (risk of worsening hyperglycemia is significant)
• Women with active pituitary adenoma
• Women with untreated or undertreated hypothyroidism (treat the thyroid first)
• Women with pre-existing fluid-retention conditions (heart failure, severe renal impairment, hepatic cirrhosis)

Symptoms That Should Prompt an Unscheduled Lab Check

Do not wait for the 3-month mark if you experience any of the following:

• Significant finger swelling, ankle edema, or carpal tunnel symptoms (may signal GH excess)
• Fasting blood glucose above 126 mg/dL on home monitoring
• New or worsening headaches, particularly positional or associated with visual changes
• Unusual fatigue, unexplained weight gain, or cold intolerance (check thyroid)
• Irregular periods or new amenorrhea in a woman who was previously cycling normally
• Joint pain out of proportion to activity level

Any of these warrants an unscheduled IGF-1 and metabolic panel before continuing the next dose.

A Note on the Evidence Gap

CJC-1295 clinical trial data comes from a small number of short-duration studies. The Teichman 2006 trial included healthy men and women but was not powered to report sex-stratified outcomes. Women have historically been under-represented in growth hormone and peptide clinical trials. The monitoring protocol described in this article draws on:

1. The Teichman pharmacokinetic and pharmacodynamic data
2. The Endocrine Society's 2011 Clinical Practice Guideline on GH Deficiency in Adults, which does address sex-specific IGF-1 norms
3. Known female-specific physiology around the GH-IGF-1 axis
4. General principles of GH excess monitoring adapted from acromegaly management guidelines

No published randomized controlled trial has prospectively evaluated a CJC-1295 monitoring protocol specifically in women across life stages. That gap is real. Any clinician who tells you otherwise is overstating the evidence. What exists is a rational, physiology-grounded framework built from adjacent data. That is not the same as a level-one evidence protocol, and you deserve to know the difference.

Working with Your Clinician

Your prescribing clinician should be reviewing your IGF-1 trend, not just checking whether it is "in range." A result that climbs from the 40th percentile at baseline to the 90th percentile at 6 months on a stable dose is worth discussing even if it is technically normal, because it suggests your sensitivity to the drug is higher than average.

Bring your lab printout to every visit, note the cycle day you were drawn, note whether you took the drug that week, and note any symptoms. That context is what lets your clinician make a genuinely informed dose decision.

The FDA's 503A compounding framework means CJC-1295 is not approved for any indication. Your prescription must come from a licensed clinician who has determined that an FDA-approved alternative does not meet your medical needs. Make sure your prescriber has documented that clinical rationale. If you are ever asked to buy CJC-1295 without a prescription, that is not a compounding pharmacy arrangement. It is an unregulated purchase of a research chemical, and no monitoring framework makes that safe.

Draw your next IGF-1 at 4 to 6 weeks after dose stabilization, early in your follicular phase if you are still cycling, and bring the result to your clinician before your next injection.